The funding, provided by the Chan Zuckerberg Initiative, will help test and study the Bay Area population in general as well as healthcare workers in particular.
In PLOS this week: CLCA2 expression linked to survival among African-American women with aggressive breast cancer, gene alterations linked to hearing loss, and more.
The firms plan to discover and develop fully human neutralizing antibodies that target the SARS-CoV-2 virus, combining Adaptive's and Amgen's respective expertise.
UK-based Abcam has also taken an undisclosed equity stake in BrickBio, located in Boston, and will work with the company to further develop its platform.